Focus IR Interview – Positive OX-1 Toxicology Results, Partner Interest & Human Trials mel | 15 May 2026
ADVFN Interview – TheraCryf Strengthens Ox-1’s Path to Market with Patent Expansion and Scalable Manufacturing Breakthroughs mel | 22 April 2026
